IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Immix Biopharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$8.22+0.24 (+3.01%)
Close on Oct 19, 2026
- Market cap
- $524.20M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
78.6%
56M of 72M shares
Institutional holders
109
45 new, 11 sold out
Net institutional buying
34M
In Q2 2026
Insider trades, 12 months
2 buys · 0 sales
Net bought $10.04K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | 9,783,192 | 14.00% | 13G (passive) amendment | Jun 30, 2026 |
| Janus Henderson Group PLC | 9,090,732 | 13.00% | 13G (passive) amendment | May 29, 2026 |
| Eventide Asset Management, LLC | 3,891,019 | 5.60% | 13G (passive) | Jun 30, 2026 |
| Saturn V Capital Management LP | 3,693,585 | 6.97% | 13G (passive) | Dec 26, 2025 |
| Millennium Management LLC | 2,812,230 | 5.30% | 13G (passive) | Mar 13, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMMX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 9,783,192 | 13.68% | $100.82M | New | 0.04% |
| Saturn V Capital Management LP | 4,658,429 | 6.51% | $48.03M | +964,844 | 6.89% |
| Eventide Asset Management, LLC | 3,891,019 | 5.44% | $40.12M | +1,342,000 | 0.54% |
| State Street Corp | 2,996,935 | 4.19% | $30.90M | +2,805,025 | 0.00% |
| BlackRock, Inc. | 2,989,972 | 4.18% | $30.83M | +2,521,595 | 0.00% |
| Deep Track Capital, LP | 2,775,000 | 3.88% | $28.61M | New | 0.42% |
| Vanguard Capital Management LLC | 2,507,122 | 3.50% | $25.85M | +719,128 | 0.00% |
| Opaleye Management Inc. | 2,345,000 | 3.28% | $24.18M | New | 2.19% |
| Millennium Management LLC | 2,066,426 | 2.89% | $21.30M | +316,226 | 0.01% |
| UBS Group AG | 1,941,817 | 2.71% | $20.02M | +1,864,985 | 0.00% |
| Marshall Wace, Llp | 1,794,908 | 2.51% | $18.51M | +153,356 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 1,739,919 | 2.43% | $17.94K | +1,324,918 | 0.00% |
| Wellington Management Group Llp | 1,473,409 | 2.06% | $15.19M | New | 0.00% |
| Great Point Partners LLC | 1,277,642 | 1.79% | $13.17M | +927,642 | 2.49% |
| Geode Capital Management, LLC | 1,201,097 | 1.68% | $12.39M | +737,713 | 0.00% |
| Velan Capital Investment Management LP | 1,085,000 | 1.52% | $11.19M | +345,000 | 6.81% |
| Logos Global Management LP | 1,000,000 | 1.40% | $10.31M | −225,000 | 0.44% |
| Bleichroeder LP | 1,000,000 | 1.40% | $10.31M | – | 1.84% |
| Franklin Resources Inc | 969,120 | 1.35% | $9.99M | +54 | 0.00% |
| Burkehill Global Management, LP | 544,118 | 0.76% | $5.61M | +250,000 | 0.20% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 109 | 56M | 78.6% | 45 / 35 | 13 / 11 | 35M | 1M |
| Q1 2026 | 77 | 27M | 37.8% | 24 / 28 | 13 / 12 | 8M | 4M |
| Q4 2025 | 67 | 24M | 34.1% | 41 / 17 | 6 / 5 | 22M | 0M |
| Q3 2025 | 31 | 3M | 3.9% | 12 / 7 | 4 / 4 | 1M | 0M |
| Q2 2025 | 23 | 2M | 3.2% | 5 / 5 | 4 / 4 | 0M | 1M |
| Q1 2025 | 22 | 3M | 4.1% | 3 / 4 | 9 / 4 | 0M | 0M |
| Q4 2024 | 23 | 3M | 4.0% | 5 / 4 | 6 / 7 | 0M | 1M |
| Q3 2024 | 25 | 4M | 5.7% | 1 / 6 | 4 / 6 | 0M | 1M |
| Q2 2024 | 31 | 4M | 6.2% | 5 / 5 | 12 / 6 | 0M | 1M |
| Q1 2024 | 35 | 5M | 7.3% | 14 / 13 | 4 / 7 | 5M | 0M |
| Q4 2023 | 28 | 1M | 1.1% | 13 / 7 | 3 / 1 | 0M | 0M |
| Q3 2023 | 16 | 0M | 0.6% | 3 / 8 | 0 / 5 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of IMMX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Eventide Healthcare & Life Sciences Fund | 3,891,019 | 5.44% | $40.12M | 2.24% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,104,035 | 2.94% | $21.69M | 0.20% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,780,495 | 2.49% | $18.36M | 0.00% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,326,256 | 1.85% | $13.67M | 0.11% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,067,981 | 1.49% | $11.01M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 681,413 | 0.95% | $7.03M | 0.01% | Jun 30, 2026 |
| Columbia Small Cap Value Discovery Fund | 483,630 | 0.68% | $4.02M | 0.16% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 449,259 | 0.63% | $3.74M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 370,703 | 0.52% | $3.82M | 0.02% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 357,034 | 0.50% | $2.97M | 0.26% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 298,586 | 0.42% | $2.69M | 0.01% | May 31, 2026 |
| Timber Point Global Allocations Fund | 140,000 | 0.20% | $1.44M | 4.51% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 138,125 | 0.19% | $1.42M | 0.09% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 109,438 | 0.15% | $984.94K | 0.00% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 99,794 | 0.14% | $830.29K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ilya M. Rachman | CEO and Chairman, Director | 1,141,683 | 1.60% | May 29, 2026 |
| Gabriel S. Morris | CFO, President, Director | 718,273 | 1.00% | May 29, 2026 |
| Jane Buchan | Director | 28,705 | 0.04% | May 29, 2026 |
| Helen C. Adams | Director | 181,004 | 0.25% | May 29, 2026 |
| Magda Marquet | Director | 72,342 | 0.10% | May 29, 2026 |
| Jason Hsu | Director | 4,815,163 | 6.73% | May 29, 2026 |
| Nancy T. Chang | Director | 925,130 | 1.29% | May 29, 2026 |
| Carey Ng | Director | 1,051,471 | 1.47% | May 29, 2026 |
| Yekaterina Chudnovsky | Director | 3,247,326 | 4.54% | May 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Nancy T. Chang Director | May 22, 2026 | Award | +6,250 | – | – | 428,190 |
| Magda Marquet Director | May 22, 2026 | Award | +6,250 | – | – | 52,342 |
| Yekaterina Chudnovsky Director | May 22, 2026 | Award | +6,250 | – | – | 6,250 |
| Jason Hsu Director | May 22, 2026 | Award | +6,250 | – | – | 899,250 |
| Helen C. Adams Director | May 22, 2026 | Award | +6,250 | – | – | 181,004 |
| Jane Buchan Director | May 22, 2026 | Award | +6,250 | – | – | 28,705 |
| Carey Ng Director | May 22, 2026 | Award | +6,250 | – | – | 26,250 |
| Ilya M. Rachman CEO and Chairman, Director | Dec 10, 2025 | Buy | +746 | $6.67 | $4.98K | 1,141,683 |
| Gabriel S. Morris CFO, Director | Dec 10, 2025 | Buy | +770 | $6.58 | $5.07K | 291,429 |
| Gabriel S. Morris CFO, Director | Dec 8, 2025 | Option exercise | +156,000 | $0.80 | $124.80K | 426,844 |
| Ilya M. Rachman CEO and Chairman, Director | Sep 17, 2025 | Buy | +2,500 | $2.02 | $5.05K | 1,140,937 |
| Gabriel S. Morris CFO, Director | Sep 16, 2025 | Buy | +2,600 | $1.97 | $5.12K | 290,659 |
| Ilya M. Rachman CEO and Chairman, Director | Jun 18, 2025 | Buy | +2,178 | $2.30 | $5.01K | 1,138,437 |
| Gabriel S. Morris CFO, Director | Jun 18, 2025 | Buy | +2,225 | $2.28 | $5.07K | 288,059 |
| Jason Hsu Director | Dec 23, 2024 | Buy | +40,000 | $2.19 | $87.60K | 893,000 |
| Jason Hsu Director | Dec 20, 2024 | Buy | +7,700 | $2.17 | $16.71K | 853,000 |
| Jason Hsu Director | Aug 22, 2024 | Buy | +8,100 | $2.25 | $18.23K | 845,300 |
| Jason Hsu Director | Aug 21, 2024 | Buy | +15,000 | $2.23 | $33.45K | 837,200 |
| Carey Ng Director | Aug 16, 2024 | Buy | +10,000 | $1.86 | $18.60K | 20,000 |
| Jason Hsu Director | Jul 24, 2024 | Buy | +6,000 | $2.15 | $12.90K | 822,200 |
| Jason Hsu Director | Jul 18, 2024 | Buy | +3,200 | $2.07 | $6.62K | 816,200 |
| Ilya M. Rachman CEO and Chairman, Director | Jun 7, 2024 | Buy | +2,600 | $2.13 | $5.54K | 1,136,259 |
| Gabriel S. Morris CFO, Director | Jun 7, 2024 | Buy | +2,500 | $2.12 | $5.30K | 285,834 |
| Gabriel S. Morris CFO, Director | Jun 4, 2024 | Buy | +3,300 | $1.81 | $5.97K | 283,334 |
| Ilya M. Rachman CEO and Chairman, Director | Jun 4, 2024 | Buy | +3,300 | $1.81 | $5.97K | 1,133,659 |
| Gabriel S. Morris CFO, Director | May 20, 2024 | Award | +24,141 | – | – | 270,844 |
| Gabriel S. Morris CFO, Director | May 20, 2024 | Award | +194,218 | – | – | 280,034 |
| Gabriel S. Morris CFO, Director | May 20, 2024 | Award | +24,141 | – | – | 24,141 |
| Magda Marquet Director | May 20, 2024 | Award | +21,155 | – | – | 46,092 |
| Ilya M. Rachman CEO and Chairman, Director | May 20, 2024 | Award | +218,359 | – | – | 1,130,359 |
| Helen C. Adams Director | May 20, 2024 | Award | +74,241 | – | – | 174,754 |
| Jane Buchan Director | May 20, 2024 | Award | +1,127 | – | – | 22,455 |
| Magda Marquet Director | May 15, 2024 | Award | +25,002 | – | – | 25,002 |
| Helen C. Adams Director | May 15, 2024 | Award | +87,740 | – | – | 100,740 |
| Jane Buchan Director | May 15, 2024 | Award | +1,332 | – | – | 21,332 |
| Gabriel S. Morris CFO, Director | May 14, 2024 | Buy | +4,500 | $2.23 | $10.04K | 85,816 |
| Ilya M. Rachman CEO and Chairman, Director | May 14, 2024 | Buy | +4,300 | $2.25 | $9.68K | 912,000 |
| Jason Hsu Director | Dec 11, 2023 | Buy | +31,000 | $4.67 | $144.77K | 813,000 |
| Jason Hsu Director | Dec 8, 2023 | Buy | +25,000 | $4.88 | $122.00K | 782,000 |
| Jason Hsu Director | Sep 15, 2023 | Buy | +7,000 | $2.49 | $17.43K | 757,000 |
| Jason Hsu Director | Sep 14, 2023 | Buy | +10,000 | $2.58 | $25.80K | 750,000 |
| Carey Ng Director | Sep 14, 2023 | Buy | +10,000 | $2.58 | $25.80K | 10,000 |
| Jason Hsu Director | Sep 12, 2023 | Buy | +30,000 | $2.83 | $84.90K | 740,000 |
| Helen C. Adams Director | Sep 12, 2023 | Buy | +13,000 | $2.96 | $38.48K | 13,000 |
| Jason Hsu Director | Sep 11, 2023 | Buy | +25,000 | $2.89 | $72.25K | 710,000 |
| Jason Hsu Director | Sep 8, 2023 | Buy | +10,000 | $2.53 | $25.30K | 685,000 |
| Jane Buchan Director | Sep 7, 2023 | Buy | +20,000 | $2.46 | $49.20K | 20,000 |
| Magda Marquet Director | Sep 6, 2023 | Buy | +9,000 | $2.47 | $22.23K | 20,000 |
| Magda Marquet Director | Sep 5, 2023 | Buy | +10,000 | $2.47 | $24.70K | 11,000 |
| Magda Marquet Director | Aug 31, 2023 | Buy | +1,000 | $2.01 | $2.01K | 1,000 |
| Ilya M. Rachman CEO and Chairman, Director | Nov 14, 2022 | Buy | +1,000 | $0.95 | $950 | 907,550 |
| Ilya M. Rachman CEO and Chairman, Director | Nov 14, 2022 | Buy | +4,050 | $1.02 | $4.13K | 906,550 |
| Ilya M. Rachman CEO and Chairman, Director | Nov 14, 2022 | Buy | +150 | $0.99 | $149 | 907,700 |
| Gabriel S. Morris CFO, Director | Nov 14, 2022 | Buy | +5,200 | $0.94 | $4.89K | 81,316 |
| Sean Senn – | Jul 14, 2022 | Sale | −200 | $2.75 | $550 | 899,800 |
| Sean Senn 10% owner | Jul 14, 2022 | Sale | −200 | $2.75 | $550 | 899,800 |
| Vladimir P. Torchilin Scientific Co-Founder | Dec 20, 2021 | Buy | +3,000 | $5.00 | $15.00K | 905,200 |
| Carey Ng Director | Dec 20, 2021 | Conversion | +1,000,221 | $0.85 | $850.19K | 1,000,221 |
| Carey Ng Director | Dec 20, 2021 | Buy | +25,000 | $5.00 | $125.00K | 1,025,221 |
| Jason Hsu Director | Dec 20, 2021 | Buy | +50,000 | $5.00 | $250.00K | 50,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.